FDA hearing: psychedelics launch needs balanced regulation without limiting access
The area of psychedelic therapeutics has been rapidly growing in research and drug development with the advent of classical psychedelics …
Post
-
-
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first …
-
Novo targets oral macrocycles with $1.4bn Orbis partnership
Novo has teamed up with macrocycle specialist Orbis Medicines in a deal worth up to $1.4bn, marking an effort by …
-
Ona Therapeutics to develop ADC with WuXi’s payload-linker platform
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker …
-
Roche agrees to $1bn deal with Dualitas for bispecific antibody research
Roche and Dualitas Therapeutics have entered a research collaboration and licence agreement that could reach a potential value of up …
-
The shrinking return on investment for Nordic innovation
Despite the region’s reputation as a thriving hub of innovation, Nordic biotechs are having a hard time funding the jump …
-
Novo taps Anthropic’s Claude to ‘supercharge’ R&D efforts
Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain …
-
Cellares and GenomeFrontier to assess automated GF-CART01 production
Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated manufacturing for the latter’s investigational CAR-T cell therapy, GF-CART01, …
-
Viatris’ Wakix receives Japanese approval to treat OSAS and narcolepsy
Japan’s Ministry of Health, Labour and Welfare has approved Viatris’ Wakix (pitolisant) for excessive daytime sleepiness (EDS) related to obstructive …
-
Sling ropes in $123m for oral thyroid eye disease drug
Sling Therapeutics has raised $123m to propel its thyroid eye disease (TED) pill through a pivotal clinical trial. The funds, which …
-
Looking beyond short-term turmoil, Syngene is investing for the future
These are transitional times for Syngene, the Bengaluru, India-headquartered contract research, development, and manufacturing organisation (CRDMO). It already has an …
-
ERS 2026: obesity, an independent obstruction to biologic-treated asthma
On 7 September at the European Respiratory Society (ERS) 2026 Annual Meeting, investigators from the University of Siena presented their …
-
Gilead and PAHO agree to expedite lenacapavir access for HIV prevention
Gilead Sciences and the Pan American Health Organization (PAHO) have signed an agreement to expedite access to the company’s twice-yearly …
-
Eli Lilly and QurCan sign genetic medicine deal
Eli Lilly and Company and QurCan Therapeutics have signed an exclusive research and collaboration agreement to develop genetic medicine therapeutics …
-
Electra targets $342m IPO to fund hyperinflammatory syndrome drug’s pivotal trials
Electra Therapeutics has unveiled that it plans to raise up to $341.9m in an initial public offering (IPO), with the …
